prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, Clinical Diagnosis & History: Internal development of enhancing mass on MRI left breast, core biopsy. showed infiltrating ductal carcinoma (IFDC) and DCIS, history of right. infiltrating ductal carcinoma 0.3 cm 0/6 sentinel lymph node, status post. right TM sentinel lymph node biopsy 8/05. Specimens Submitted: 1: SP: Sentinel node #1, level 1, left axilla (fs). 2: SP: Sentinel node #2, level 2, left axilla (fs) (. 3: SP: Left breast. 4: SP: Nonsentinel nous left axilla. DIAGNOSIS: 1). LYMPH NODE, SENTINEL #1 LEVEL I LEFT AXILLA; EXCISION: - METASTATIC CARCINOMA IN THE FORM OF MICROSCOPIC CLUSTERS AND SINGLE. CELLS, MEASURING 0.5 MM (MICROMETASTATIC) IS IDENTIFIED IN ONE LYMPH NODE. (1/1) ON ADDITIONAL H&E STAINED SECTIONS AND CYTOKERATINS. IMMUNOHISTOCHEMCIAL STAINS (AE1:AE3). - THERE IS NO EXTRACAPSULAR EXTENSION OF CARCINOMA. 2). LYMPH NODE, SENTINEL #2 LEVEL II LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODE (0/1). - ADDITIONAL HE STAINED SECTIONS AND IMMUNOHISTOCHEMICAL STAINS FOR. CYTOKERATINS AE1:AE3) SHOW NO EVIDENCE OF METASTATIC CARCINOMA. 3). BREAST, LEFT; MASTECTOMY: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, POORLY DIFFERENTIATED,. HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE FORMATION), NUCLEAR GRADE. III/III (MARKED VARIATION IN SIZE AND SHAPE). , MEASURING 1.1 CM IN LARGEST. DIMENSION MICROSCOPICALLY. DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE, WITH HIGH. NUCLEAR GRADE AND MINIMAL NECROSIS. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH THE INVASIVE COMPONENT. - LOBULAR CARCINOMA IN SITU (LCIS) IS ALSO IDENTIFIED, CLASSICAL TYPE (TYPE. A) INVOLVING SCLEROSING ADENOSIS. THE INVASIVE CARCINOMA IS LOCATED IN THE UPPER OUTER QUADRANT. - THE DCIS IS LOCATED IN THE UPPER OUTER QUADRANT. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA IS. IDENTIFIED. CALCIFICATIONS ARE PRESENT IN THR IN SITU AND INVASIVE CARCINOMA, AND IN. BENIGN BREAST PARENCHYMA. - NO VASCULAR INVASION IS NOTED. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. - NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE SKIN SHOWS SEBORRHEIC KERATOSIS. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE CHANGES, EXTENSIVE. SCLEROSING ADENOSIS, RADIAL SCAR, ATYPICAL DUCTAL HYPERPLASIA (ADK),. INTRADUCTAL SCLEROSED PAPILLOMA WITH FOCAL ATYPIA, FIBROADENOMA AND CYST. FORMATION. - RESULTS OF SPECIAL STAINS (ER, PR, HER2-NEU) ARE AS FOLLOW: Immunohistochemical stains were performed on formalin-fixed tissue with the. following results for invasive carcinoma (block 6) : ESTROGEN RECEPTOR. 95% nuclear staining with strong intensity. PROGESTERONE RECEPTOR. 0% nuclear staining. HER2 (HercepTest;. Negative (0 / 1+). (1% of invasive tumor cells exhibit complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). Controls are satisfactory. Comment: HercepTestTM ( 1 is an FDA-approved method for assessment of. HER2 protein overexpression in breast cancer tissue routinely processed for. histological evaluation. The HER2 test results are reported in accordance. with the ASCO/CAP guideline recommendations for HER2 testing in breast. cancer (J Clin Oncol 2007; 25 (1) :1-28) . 4). LYMPH NODE, NON-SENTINEL LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODE (0/1) -. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: MD. 1). The specimen is received fresh for frozen section consultation, labeled. Sentinel mode #1, level 1, left axilla" and consists of a single yellow-tan. firm and fatty lymph node measuring 4.7 cm. The node is trisected and two. half are submitted for frozen section in cassettes labeled as A and B. The. remaining fatty portion is bisected and entirely submitted for permanent. section. Summary of sections: FSC-A -- frozen section control-A. FSC-Bfrozen section control B. RLN- remaining lymph node. 2). The specimen is received fresh for frozen section consultation,. labeled "Sentinel node #2, level 2, left axilla" and consists of a single. pink-tan - fatty lymph node measuring 1.6 cm in greatest dimension. Bisected. and entirely submitted for frozen section. Summary of sections: FSC -- frozen section control. .D. 3). The specimen is received fresh, labeled "left breast, stitch marks. axillary tail" and consists of a breast measuring 25 x 24 x 4 cm with. overlying skin ellipse measuring 24 x 7.5 cm. Situated central/superiorly. on the skin surface is an everted nipple measuring 1.0 x 0.9 x 0.5 cm and. areola measuring 3.0 x 2.7 cm. The skin shows a raised pigmented lesion. measuring 1.0 x 0.5 x 0.2 cm, located 1.8 cm medial to the areola. No scar. is grossly identified on the skin surface. A suture demarcates the axillary. aspect. The posterior surface of the breast is inked black and the radial. margin is inked blue. The specimen is serially sectioned to reveal a firm,. white, well-circumscribed mass measuring 1.0 x 1.0 x 0.9 cm, located within. the upper outer quadrant at the two o'clock aspect, 1.2 cm from the deep. margin. A hemorrhagic biopsy site is associated with the mass. An irregular. area of white fibroglandular tissue is located immediately medial to the. mass and measures approximately 5 x 5 x 3 cm. No additional discrete masses. are grossly identified. Sectioning of the axillary aspect reveals no grossly. identifiable lymph nodes. Representative sections are submitted. TPS is. taken. Summary of sections: N - nipple with nipple base. S - skin with pigmented lesion. D - deep margin. BX - biopay site. T - tumor, entirely submitted. FG - dense fibroglandular tissue medial to the mass. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. M.D. 4). The specimen is received in formalin, labeled "non-sentinel node left. axilla" and consists a single lymph node with surrounding fibrofatty tissue. measuring 1.2 x 0.4 cm. The lymph node is bisected and entirely submitted. Summary of sections: U-undesignated. Summary of Sections: Part 1: SP: Sentinel node #1, level 1, left axilla (fs). Block. Sect. Site. PCs. 1. FSC-A. 1. 1. FSC-B. 1. 1. RLN. 3. Part 2: SP: Sentinel node #2, level 2, left axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 3: SP: Left breast (sr). Block. Sect. Site. PC's. 2. BX. 2. 1. D. 1. 9. FG. 9. 1. LIQ. 1. 1. LOQ. 1. 1. N. 1. 1. s. 1. 2. 2. 1. UIQ. 1. 1. UOQ. 1. Part 4: SP: Nonsentinel node left axilla. Block. Sect. Site. PCs. 1. U. 1. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the. tissue sample examined at the time of the intraoperative. consultation. 1). FROZEN SECTION DIAGNOSIS: GROSSLY LARGE AND FATTY LYMPH. NODE. REPRESENTATIVE SECTIONS FROZEN AND SHOW NO TUMOR ON FROZEN SECTION. PERMANENT DIAGNOSIS: SAME. ., MD.

expanded version (tokens=2554) : 
 Summary of key points from the breast pathology report:

- Clinical diagnosis and history: Internal development of enhancing mass on MRI left breast; core biopsy showed infiltrating ductal carcinoma (IDC) and DCIS
- Histological classification: Luminal A subtype
- Subtype of cancer: IDC, with DCIS present
- Necrosis: Minimal necrosis present in DCIS
- Tumor infiltrating lymphocytes: No mention of tumor infiltrating lymphocytes
- Histological grade: IDC is poorly differentiated, histologic grade III/III (slight or no tubule formation), nuclear grade III/III (marked variation in size and shape), DCIS is solid type with high nuclear grade
- Lymphovascular invasion: No vascular invasion noted
- Calcification: Calcifications present in DCIS and invasive carcinoma, and in benign breast parenchyma
- Receptor status: ER positive (95% nuclear staining with strong intensity), PR negative (0% nuclear staining), HER2 negative (0/1+ with 1% of invasive tumor cells exhibiting complete membranous staining)
- Ancillary testing results: No extracapsular extension of carcinoma; lobular carcinoma in situ (LCIS) also identified, classical type (type A) involving sclerosing adenosis; no involvement of nipple by either in situ or invasive carcinoma identified; no involvement of surgical margins by either invasive or in situ carcinoma identified; no skin involvement by carcinoma identified; non-ne

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2702) : 
 The breast pathology report shows the presence of LumA subtype IDC and DCIS with minimal necrosis. The IDC is poorly differentiated, histological grade III/III, nuclear grade III/III with ER 95% and PR 0% nuclear staining. HER2 is negative (0/1+). No tumor infiltrating lymphocytes were identified, and there was no extracapsular extension or vascular invasion observed. Calcifications were present but surgical margins were free from invasive or in situ carcinoma.

